Conformational flexibility determines selectivity and antibacterial, antiplasmodial,andanticancer potency of cationic -αhelical peptides

Journal of Biological Chemistry

Volumn 287, Issue 41, 2012, Pages 34120-34133

  Vermeer, Louic S ^a   Lan, Yun ^a,b,c   Abbate, Vincenzo ^a   Ruh, Emrah ^c   Bui, Tam T ^a   Wilkinson, Louise J ^a   Kanno, Tokuwa ^a   Jumagulova, Elmira ^a   Kozlowska, Justyna ^a   Patel, Jayneil ^a   McIntyre, Caitlin A ^a   Yam, W C ^d   Siu, Gilman ^d   Atkinson, R Andrew ^e   Lam, Jenny K W ^b   Bansal, Sukhvinder S ^a   Drake, Alex F ^a   Mitchell, Graham H ^c   Mason, A James ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-BACTERIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; CANCER CELL LINES; CANCEROUS CELLS; CONFORMATIONAL FLEXIBILITY; CYTOTOXIC ACTIVITIES; DISORDERED STRUCTURES; GRAM-NEGATIVE BACTERIA; HELICAL PEPTIDE; HELIX CONTENT; HYDROPHOBIC AMINO ACIDS; INTRACELLULAR PATHOGENS; MYCOBACTERIUM TUBERCULOSIS; PHOSPHATE IONS; PLASMODIUM FALCIPARUM; POSITIVELY CHARGED; PROLINE RESIDUES;

CELL CULTURE; ENZYME ACTIVITY; MAMMALS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDES;

AMINO ACIDS;

LYSYLLYSYLALANYLLEUCYLHISTIDINYLALANYLLEUCYLLYSYLLYSYLTRYPTOPHYLLEUCYLPROPYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLHISTIDINYLLEUCYLALANYLLYSYLLYSINAMIDE; LYSYLLYSYLALANYLLEUCYLLYSYLALANYLLEUCYLLYSYLHISTIDINYLTRYPTOPHYLLEUCYLPROPYLALANYLLEUCYLHISTIDINYLLYSYLLEUCYLALANYLLYSYLALANYLLYSYLLYSINAMIDE; LYSYLLYSYLALANYLLEUCYLLYSYLLHISTIDINYLALANYLLEUCYLALANYLLYSYLTRYPTOPHYLLEUCYLPROPYLALANYLLEUCYLLYSYLALANYLLEUCYLALANYLHISTIDINYLLYSYLLEUCYLALANYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLALANYLLYSYLLYSYLTRYPTOPHYLLEUCYLALANYLLEUCYLALANYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLALANYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLALANYLLYSYLLYSYLTRYPTOPHYLLEUCYLPROPYLLEUCYLALANYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLALANYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLPROPYLLEUCYLTRYPTOPHYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLPROPYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLALANYLPROPYLLYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLLYSYLLEUCYLALANYLLEUCYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLHISTIDINYLALANYLLEUCYLLYSYLLYSYLTRYPTOPHYLLEUCYLHISTIDINYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLHISTIDINYLLEUCYLALANYLLEUCYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLYSYLTRYPTOPHYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLYSYLTRYPTOPHYLLEUCYLPROPYLALANYLLEUCYLLYSYLLYSYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLYSINAMIDE; LYSYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLEUCYLLEUCYLALANYLPROPYLLEUCYLTRYPTOPHYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLEUCYLPROPYLALANYLLEUCYLLEUCYLTRYPTOPHYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLALANYLLYSYLALANYLPROPYLLYSYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLLYSYLLEUCYLALANYLLEUCYLALANYLLYSYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLALANYLLEUCYLALANYLLEUCYLLYSYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLLYSYLLEUCYLALANYLLEUCYLALANYLLYSYLLEUCYLALANYLPROPYLLEUCYLTRYPTOPHYLLYSYLALANYLLEUCYLALANYLLEUCYLLYSYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLLYSYLLEUCYLALANYLLEUCYLALANYLLYSYLPROPYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLALANYLLEUCYLALANYLLEUCYLLYSYLLEUCYLLYSYLLYSYLALANINAMIDE; LYSYLLYSYLLEUCYLLYSYLLEUCYLALANYLPROPYLALANYLLYSYLLEUCYLALANYLLEUCYLLEUCYLTRYPTOPHYLLYSYLALANYLLEUCYLALANYLLEUCYLLYSYLLEUCYLLYSYLLYSYLALANINAMIDE; PHENYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; PHENYLALANYLPHENYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; PHENYLALANYLPHENYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLALANYLPROPYLLYSYLLEUCYLLEUCYLALANYLLEUCYLLEUCYLALANYLLEUCYLLYSYLLEUCYLALANYLLYSYLALANYLLEUCYLLYSYLLYSYLALANINAMIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPLASMODIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICE; MYCOBACTERIUM TUBERCULOSIS; PLASMODIUM FALCIPARUM; PROTEIN STRUCTURE, SECONDARY;

EID: 84867259108     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.359067     Document Type: Article

References (58)

1. Hancock, R. E., and Sahl, H. G. (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551-1557 (Pubitemid 44967479)
2. Reddy, K. V., Yedery, R. D., and Aranha, C. (2004) Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 24, 536-547 (Pubitemid 39536106)
3. Marr, A. K., Gooderham, W. J., and Hancock, R. E. (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6, 468-472 (Pubitemid 44340665)
4. Gordon, Y. J., Romanowski, E. G., and McDermott, A. M. (2005) A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30, 505-515 (Pubitemid 41113552)
5. Brogden, K. A. (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250
6. Dathe, M., and Wieprecht, T. (1999) Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1462, 71-87
7. Zhang, L., Benz, R., and Hancock, R. E. (1999) Influence of proline residues on the antibacterial and synergistic activities of α-helical peptides. N-terminal analogs of cecropin A: synthesis, antibacterial activity, and conformational properties. Biochemistry 38, 8102-8111
8. Andreu, D., Merrifield, R. B., Steiner, H., and Boman, H. G. (1985) N-terminal analogs of cecropin A: synthesis, antibacterial activity, and conformational properties. Biochemistry 24, 1683-1688 (Pubitemid 15089160)
9. Gazit, E., Boman, A., Boman, H. G., and Shai, Y. (1995) Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Biochemistry 34, 11479-11488
10. Chen, H. C., Brown, J. H., Morell, J. L., and Huang, C. M. (1988) Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett. 236, 462-466
11. Song, Y. M., Yang, S. T., Lim, S. S., Kim, Y., Hahm, K. S., Kim, J. I., and Shin, S. Y. (2004) Effects of L- or D-Pro incorporation into hydrophobic or hydrophilic face of amphipathic α-helical model peptide on structure and cell selectivity. Biochem. Biophys. Res. Commun. 314, 615-621 (Pubitemid 38084763)
12. Yang, S. T., Lee, J. Y., Kim, H. J., Eu, Y. J., Shin, S. Y., Hahm, K. S., and Kim, J. I. (2006) Contribution of a central proline in model amphipathic α-helical peptides to self-association, interaction with phospholipids, and antimicrobial mode of action. FEBS J. 273, 4040-4054 (Pubitemid 44253657)
13. Tatham, A. S., Hider, R. C., and Drake, A. F. (1983) The effect of counterions on melittin aggregation. Biochem. J. 211, 683-686
14. Wiegand, I., Hilpert, K., and Hancock, R. E. (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163-175 (Pubitemid 351266501)
15. Bacon, D. J., Latour, C., Lucas, C., Colina, O., Ringwald, P., and Picot, S. (2007) Comparison of a SYBR Green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob. Agents Chemother. 51, 1172-1178 (Pubitemid 46586790)
16. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589-601 (Pubitemid 18056527)
17. Sreerama, N., and Woody, R. W. (2000) Estimation of protein secondary structure from CD spectra: comparison of CONTIN, SELCON and CDSSTR methods with an expanded reference set. Anal. Biochem. 287, 252-260 (Pubitemid 32006234)
18. Ladokhin, A. S., Jayasinghe, S., and White, S. H. (2000) How to measure and analyze tryptophan fluorescence in membranes properly, and why bother? Anal. Biochem. 285, 235-245
19. Goddard, T. D., and Kneller, D. G. (2008) SPARKY 3, University of California, San Francisco
20. Rieping, W., Habeck, M., Bardiaux, B., Bernard, A., Malliavin, T. E., and Nilges, M. (2007) ARIA2: automated NOE assignment and data integration in NMR structure calculation. Bioinformatics 23, 381-382 (Pubitemid 46323164)
21. Fossi, M., Oschkinat, H., Nilges, M., and Ball, L. J. (2005) Quantitative study of the effects of chemical shift tolerances and rates of SA cooling on structure calculation from automatically assigned NOE data. J. Magn. Reson. 175, 92-102 (Pubitemid 40753510)
22. Laskowski, R. A., Rullmann, J. A., MacArthur, M. W., Kaptein, R., and Thornton, J. M. (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477-486 (Pubitemid 126706801)
23. Mason, A. J., Moussaoui, W., Abdelrahman, T., Boukhari, A., Bertani, P., Marquette, A., Shooshtarizaheh, P., Moulay, G., Boehm, N., Guerold, B., Sawers, R. J., Kichler, A., Metz-Boutigue, M. H., Candolfi, E., Prévost, G., and Bechinger, B. (2009) Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. J. Biol. Chem. 284, 119-133
24. Wieprecht, T., Dathe, M., Epand, R. M., Beyermann, M., Krause, E., Maloy, W. L., MacDonald, D. L., and Bienert, M. (1997) Influence of the angle subtended by the positively charged helix face on the membrane activity of amphipathic, antibacterial peptides. Biochemistry 36, 12869-12880 (Pubitemid 27465398)
25. Jin, Y., Hammer, J., Pate, M., Zhang, Y., Zhu, F., Zmuda, E., and Blazyk, J. (2005) Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic β-sheet and α-helical potentials. Antimicrob. Agents Chemother. 49, 4957-4964 (Pubitemid 41778906)
26. Nishikawa, M., and Ogawa, K. (2004) Occurrence of D-histidine residues in antimicrobial poly(arginyl-histidine), conferring resistance to enzymatic hydrolysis. FEMS Microbiol. Lett. 239, 255-259 (Pubitemid 39346133)
27. Hong, S. Y., Oh, J. E., and Lee, K. H. (1999) Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem. Pharmacol. 58, 1775-1780 (Pubitemid 29505418)
28. Chen, Y., Mant, C. T., Farmer, S. W., Hancock, R. E., Vasil, M. L., and Hodges, R. S. (2005) Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 280, 12316-12329
29. Bellesia, G., and Shea, J. E. (2009) What determines the structure and stability of KFFE monomers, dimers, and protofibrils? Biophys. J. 96, 875-886
30. Lan, Y., Ye, Y., Kozlowska, J., Lam, J. K., Drake, A. F., and Mason, A. J. (2010) Structural contributions to the intracellular targeting strategies of antimicrobial peptides. Biochim. Biophys. Acta 1798, 1934-1943
31. Lakowicz, J. T. (1983) Principles of Fluorescence Spectroscopy, Plenum Press, New York
32. Chen, Y., Liu, B., Yu, H. T., and Barkley, M. D. (1996) The peptide bond quenches indole fluorescence. J. Am. Chem. Soc. 118, 9271-9278 (Pubitemid 26355121)
33. Drake, A. F., Siligardi G., and Gibbons, W. A. (1988) Reassessment of the electronic circular dichroism criteria for random coil conformations of poly(L-lysine) and the implications for protein folding and denaturation studies. Biophys. Chem. 31, 143-146
34. Durfee, T., Nelson, R., Baldwin, S., Plunkett, G., 3rd, Burland, V., Mau, B., Petrosino, J. F., Qin, X., Muzny, D. M., Ayele, M., Gibbs, R. A., Csörgo, B., Pósfai, G., Weinstock, G. M., and Blattner, F. R. (2008) The complete genome sequence of Escherichia coli DH10B: insights into the biology of a laboratory workhorse. J. Bacteriol. 190, 2597-2606 (Pubitemid 351466356)
35. Aurora, R., and Rose, G. D. (1998) Helix capping. Protein Sci. 7, 21-38 (Pubitemid 28133743)
36. Yeaman, M. R., and Yount, N. Y. (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55 (Pubitemid 36268398)
37. Epand, R. M., Rotem, S., Mor, A., Berno, B., and Epand, R. F. (2008) Bacterial membranes as predictors of antimicrobial potency. J. Am. Chem. Soc. 130, 14346-14352
38. Epand, R. M., and Epand, R. F. (2011) Bacterial membrane lipids in the action of antimicrobial agents. J. Pept. Sci. 17, 298-305
39. Epand, R. F., Maloy, L., Ramamoorthy, A., and Epand, R. M. (2010) Amphipathic helical cationic antimicrobial peptides promote rapid formation of crystalline states in the presence of phosphatidylglycerol: lipid clustering in anionic membranes. Biophys. J. 98, 2564-2573
40. Epand, R. F., Maloy, W. L., Ramamoorthy, A., and Epand, R. M. (2010) Probing the "charge cluster mechanism" in amphipathic helical cationic antimicrobial peptides. Biochemistry 49, 4076-4084
41. Gregory, S. M., Pokorny, A., and Almeida, P. F. (2009) Magainin 2 revisited: a test of the quantitative model for the all-or-none permeabilization of phospholipid vesicles. Biophys. J. 96, 116-131
42. Mason, A. J., Chotimah, I. N., Bertani, P., and Bechinger, B. (2006) A spectroscopic study of the membrane interaction of the antimicrobial peptide pleurocidin. Mol. Membr. Biol. 23, 185-194 (Pubitemid 43786020)
43. Saint, N., Cadiou, H., Bessin, Y., and Molle, G. (2002) Antibacterial peptide pleurocidin forms ion channels in planar lipid bilayers. Biochim. Biophys. Acta 1564, 359-364
44. Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V., and Hancock, R. E. (2002) Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 46, 605-614 (Pubitemid 34162506)
45. Kobayashi, S., Takeshima, K., Park, C. B., Kim, S. C., and Matsuzaki, K. (2000) Interactions of the novel antimicrobial peptide buforin 2 with lipid bilayers: proline as a translocation promoting factor. Biochemistry 39, 8648-8654 (Pubitemid 30489964)
46. Kobayashi, S., Chikushi, A., Tougu, S., Imura, Y., Nishida, M., Yano, Y., and Matsuzaki, K. (2004) Membrane translocation mechanism of the antimicrobial peptide buforin 2. Biochemistry 43, 15610-15616 (Pubitemid 39647487)
47. Park, C. B., Yi, K. S., Matsuzaki, K., Kim, M. S., and Kim, S. C. (2000) Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell penetrating ability of buforin II. Proc. Natl. Acad. Sci. U.S.A. 97, 8245-8250 (Pubitemid 30639657)
48. Xiao, Y., Herrera, A. I., Bommineni, Y. R., Soulages, J. L., Prakash, O., and Zhang, G. (2009) The central kink region of fowlicidin-2, an α-helical host defense peptide, is critically involved in bacterial killing and endotoxin neutralization. J. Innate Immun. 1, 268-280
49. Kim, J. K., Lee, S. A., Shin, S., Lee, J. Y., Jeong, K. W., Nan, Y. H., Park, Y. S., Shin, S. Y., and Kim, Y. (2010) Structural flexibility and the positive charges are the key factors in bacterial cell selectivity and membrane penetration of peptoid-substituted analog of piscidin 1. Biochim. Biophys. Acta 1798, 1913-1925
50. Lee, S. A., Kim, Y. K., Lim, S. S., Zhu, W. L., Ko, H., Shin, S. Y., Hahm, K. S., and Kim, Y. (2007) Solution structure and cell selectivity of piscidin 1 and its analogues. Biochemistry 46, 3653-3663 (Pubitemid 46493466)
51. Pukala, T. L., Brinkworth, C. S., Carver, J. A., and Bowie, J. H. (2004) Investigating the importance of the flexible hinge in caerin 1.1: solution structures and activity of two synthetically modified caerin peptides. Biochemistry 43, 937-944 (Pubitemid 38141491)
52. Porcelli, F., Buck, B., Lee, D. K., Hallock, K. J., Ramamoorthy, A., and Veglia, G. (2004) Structure and orientation of pardaxin determined by NMR experiments in model membranes. J. Biol. Chem. 279, 45815-45823 (Pubitemid 39491574)
53. Park, C. B., Kim, H. S., and Kim, S. C. (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244, 253-257 (Pubitemid 28419934)
54. Papo, N., and Shai, Y. (2003) Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides 24, 1693-1703 (Pubitemid 38198076)
55. Unger, T., Oren, Z., and Shai, Y. (2001) The effect of cyclization of magainin 2 and melittin analogues on structure, function, and model membrane interactions: implication to their mode of action. Biochemistry 40, 6388-6397 (Pubitemid 32472728)
56. Avrahami, D., Oren, Z., and Shai, Y. (2001) Effect of multiple aliphatic amino acids substitutions on the structure, function, and mode of action of diastereomeric membrane active peptides. Biochemistry 40, 12591-12603 (Pubitemid 32979711)
57. Fadnes, B., Rekdal, O., and Uhlin-Hansen, L. (2009) The anticancer activity of lytic peptides in inhibited by heparan sulphate on the surface of the tumour cells. BMC Cancer 9, 183
58. Fadnes, B., Uhlin-Hansen, L., Lindin, I., and Rekdal, Ø. (2011) Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer 11, 116